1887

Abstract

European bat lyssaviruses type 1 (EBLV-1) and type 2 (EBLV-2) circulate within bat populations throughout Europe and are capable of causing disease indistinguishable from that caused by classical rabies virus (RABV). However, the determinants of viral fitness and pathogenicity are poorly understood. Full-length genome clones based on the highly attenuated, non-neuroinvasive, RABV vaccine strain (SAD-B19) were constructed with the glycoprotein (G) of either SAD-B19 (SN), of EBLV-1 (SN-1) or EBLV-2 (SN-2). characterization of SN-1 and SN-2 in comparison to wild-type EBLVs demonstrated that the substitution of G affected the final virus titre and antigenicity. , following peripheral infection with a high viral dose (10 f.f.u.), animals infected with SN-1 had reduced survivorship relative to infection with SN, resulting in survivorship similar to animals infected with EBLV-1. The histopathological changes and antigen distribution observed for SN-1 were more representative of those observed with SN than with EBLV-1. EBLV-2 was unable to achieve a titre equivalent to that of the other viruses. Therefore, a reduced-dose experiment (10 f.f.u.) was undertaken to compare EBLV-2 and SN-2, which resulted in 100 % survivorship for all recombinant viruses (SN, SN-1 and SN-2) while clinical disease developed in mice infected with the EBLVs. These data indicate that interspecies replacement of G has an effect on virus titre , probably as a result of suboptimal G–matrix protein interactions, and influences the survival outcome following a peripheral challenge with a high virus titre in mice.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.048827-0
2013-02-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/2/284.html?itemId=/content/journal/jgv/10.1099/vir.0.048827-0&mimeType=html&fmt=ahah

References

  1. Amengual B. , Whitby J. E. , King A. , Cobo J. S. , Bourhy H. . ( 1997; ). Evolution of European bat lyssaviruses. . J Gen Virol 78:, 2319–2328.[PubMed]
    [Google Scholar]
  2. Blaney J. E. , Wirblich C. , Papaneri A. B. , Johnson R. F. , Myers C. J. , Juelich T. L. , Holbrook M. R. , Freiberg A. N. , Bernbaum J. G. . & other authors ( 2011; ). Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. . J Virol 85:, 10605–10616. [CrossRef] [PubMed]
    [Google Scholar]
  3. Brookes S. M. , Aegerter J. N. , Smith G. C. , Healy D. M. , Jolliffe T. A. , Swift S. M. , Mackie I. J. , Pritchard J. S. , Racey P. A. . & other authors ( 2005; ). European bat lyssavirus in Scottish bats. . Emerg Infect Dis 11:, 572–578. [CrossRef] [PubMed]
    [Google Scholar]
  4. Buchholz U. J. , Finke S. , Conzelmann K. K. . ( 1999; ). Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. . J Virol 73:, 251–259.[PubMed]
    [Google Scholar]
  5. Cenna J. , Tan G. S. , Papaneri A. B. , Dietzschold B. , Schnell M. J. , McGettigan J. P. . ( 2008; ). Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. . Vaccine 26:, 6405–6414. [CrossRef] [PubMed]
    [Google Scholar]
  6. Cliquet F. , Aubert M. , Sagné L. . ( 1998; ). Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. . J Immunol Methods 212:, 79–87. [CrossRef] [PubMed]
    [Google Scholar]
  7. Cox J. H. , Dietzschold B. , Schneider L. G. . ( 1977; ). Rabies virus glycoprotein. II. Biological and serological characterization. . Infect Immun 16:, 754–759.[PubMed]
    [Google Scholar]
  8. Echevarría J. E. , Avellón A. , Juste J. , Vera M. , Ibáñez C. . ( 2001; ). Screening of active lyssavirus infection in wild bat populations by viral RNA detection on oropharyngeal swabs. . J Clin Microbiol 39:, 3678–3683. [CrossRef] [PubMed]
    [Google Scholar]
  9. Etessami R. , Conzelmann K. K. , Fadai-Ghotbi B. , Natelson B. , Tsiang H. , Ceccaldi P. E. . ( 2000; ). Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study. . J Gen Virol 81:, 2147–2153.[PubMed]
    [Google Scholar]
  10. Faber M. , Pulmanausahakul R. , Nagao K. , Prosniak M. , Rice A. B. , Koprowski H. , Schnell M. J. , Dietzschold B. . ( 2004; ). Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. . Proc Natl Acad Sci U S A 101:, 16328–16332. [CrossRef] [PubMed]
    [Google Scholar]
  11. Faber M. , Faber M. L. , Papaneri A. , Bette M. , Weihe E. , Dietzschold B. , Schnell M. J. . ( 2005a; ). A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. . J Virol 79:, 14141–14148. [CrossRef] [PubMed]
    [Google Scholar]
  12. Faber M. , Bette M. , Preuss M. A. , Pulmanausahakul R. , Rehnelt J. , Schnell M. J. , Dietzschold B. , Weihe E. . ( 2005b; ). Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. . J Virol 79:, 15405–15416. [CrossRef] [PubMed]
    [Google Scholar]
  13. Faber M. , Faber M. L. , Li J. , Preuss M. A. , Schnell M. J. , Dietzschold B. . ( 2007; ). Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. . J Virol 81:, 7041–7047. [CrossRef] [PubMed]
    [Google Scholar]
  14. Faul E. J. , Wanjalla C. N. , McGettigan J. P. , Schnell M. J. . ( 2008; ). Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. . Virology 382:, 226–238. [CrossRef] [PubMed]
    [Google Scholar]
  15. Faul E. J. , Aye P. P. , Papaneri A. B. , Pahar B. , McGettigan J. P. , Schiro F. , Chervoneva I. , Montefiori D. C. , Lackner A. A. , Schnell M. J. . ( 2009; ). Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. . Vaccine 28:, 299–308. [CrossRef] [PubMed]
    [Google Scholar]
  16. Finke S. , Conzelmann K. K. . ( 1999; ). Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3′ copy-back ambisense rabies virus. . J Virol 73:, 3818–3825.[PubMed]
    [Google Scholar]
  17. Finke S. , Brzózka K. , Conzelmann K. K. . ( 2004; ). Tracking fluorescence-labeled rabies virus: enhanced green fluorescent protein-tagged phosphoprotein P supports virus gene expression and formation of infectious particles. . J Virol 78:, 12333–12343. [CrossRef] [PubMed]
    [Google Scholar]
  18. Fooks A. R. , McElhinney L. M. , Pounder D. J. , Finnegan C. J. , Mansfield K. , Johnson N. , Brookes S. M. , Parsons G. , White K. . & other authors ( 2003; ). Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis. . J Med Virol 71:, 281–289. [CrossRef] [PubMed]
    [Google Scholar]
  19. Fooks A. R. , McElhinney L. M. , Marston D. A. , Selden D. , Jolliffe T. A. , Wakeley P. R. , Johnson N. , Brookes S. M. . ( 2004; ). Identification of a European bat lyssavirus type 2 in a Daubenton’s bat found in Staines, Surrey, UK. . Vet Rec 155:, 434–435.[PubMed]
    [Google Scholar]
  20. Genz B. , Nolden T. , Negatsch A. , Teifke J. P. , Conzelmann K. K. , Finke S. . ( 2012; ). Chimeric rabies viruses for trans-species comparison of lyssavirus glycoprotein ectodomain functions in virus replication and pathogenesis. . Berl Munch Tierarztl Wochenschr 125:, 219–227.[PubMed]
    [Google Scholar]
  21. Harris S. L. , Aegerter J. N. , Brookes S. M. , McElhinney L. M. , Jones G. , Smith G. C. , Fooks A. R. . ( 2009; ). Targeted surveillance for European bat lyssaviruses in English bats (2003–06). . J Wildl Dis 45:, 1030–1041.[PubMed] [CrossRef]
    [Google Scholar]
  22. Hicks D. J. , Nuñez A. , Healy D. M. , Brookes S. M. , Johnson N. , Fooks A. R. . ( 2009; ). Comparative pathological study of the murine brain after experimental infection with classical rabies virus and European bat lyssaviruses. . J Comp Pathol 140:, 113–126. [CrossRef] [PubMed]
    [Google Scholar]
  23. Horton D. L. , Voller K. , Haxton B. , Johnson N. , Leech S. , Goddard T. , Wilson C. , McElhinney L. M. , Fooks A. R. . ( 2009; ). European bat lyssavirus type 2 in a Daubenton’s bat in Scotland. . Vet Rec 165:, 383–384. [CrossRef] [PubMed]
    [Google Scholar]
  24. Horton D. L. , McElhinney L. M. , Marston D. A. , Wood J. L. , Russell C. A. , Lewis N. , Kuzmin I. V. , Fouchier R. A. , Osterhaus A. D. . & other authors ( 2010; ). Quantifying antigenic relationships among the lyssaviruses. . J Virol 84:, 11841–11848. [CrossRef] [PubMed]
    [Google Scholar]
  25. Klingen Y. , Conzelmann K. K. , Finke S. . ( 2008; ). Double-labeled rabies virus: live tracking of enveloped virus transport. . J Virol 82:, 237–245. [CrossRef] [PubMed]
    [Google Scholar]
  26. Lawson N. D. , Stillman E. A. , Whitt M. A. , Rose J. K. . ( 1995; ). Recombinant vesicular stomatitis viruses from DNA. . Proc Natl Acad Sci U S A 92:, 4477–4481. [CrossRef] [PubMed]
    [Google Scholar]
  27. Marston D. A. , McElhinney L. M. , Johnson N. , Müller T. , Conzelmann K. K. , Tordo N. , Fooks A. R. . ( 2007; ). Comparative analysis of the full genome sequence of European bat lyssavirus type 1 and type 2 with other lyssaviruses and evidence for a conserved transcription termination and polyadenylation motif in the G-L 3′ non-translated region. . J Gen Virol 88:, 1302–1314. [CrossRef] [PubMed]
    [Google Scholar]
  28. McElhinney L. M. , Marston D. A. , Leech S. , Freuling C. M. , van der Poel W. H. , Echevarria J. , Vázquez-Moron S. , Horton D. L. , Müller T. , Fooks A. R. . ( 2012; ). Molecular epidemiology of bat lyssaviruses in Europe. . Zoonoses Public Health in press. [CrossRef] [PubMed]
    [Google Scholar]
  29. McGettigan J. P. , Foley H. D. , Belyakov I. M. , Berzofsky J. A. , Pomerantz R. J. , Schnell M. J. . ( 2001; ). Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. . J Virol 75:, 4430–4434. [CrossRef] [PubMed]
    [Google Scholar]
  30. McGettigan J. P. , Pomerantz R. J. , Siler C. A. , McKenna P. M. , Foley H. D. , Dietzschold B. , Schnell M. J. . ( 2003; ). Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. . J Virol 77:, 237–244. [CrossRef] [PubMed]
    [Google Scholar]
  31. McKenna P. M. , Aye P. P. , Dietzschold B. , Montefiori D. C. , Martin L. N. , Marx P. A. , Pomerantz R. J. , Lackner A. , Schnell M. J. . ( 2004; ). Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. . J Virol 78:, 13455–13459. [CrossRef] [PubMed]
    [Google Scholar]
  32. Mebatsion T. , Konig M. , Conzelmann K. K. . ( 1996; ). Budding of rabies virus particles in the absence of the spike glycoprotein. . Cell 84:, 941–951. [CrossRef] [PubMed]
    [Google Scholar]
  33. Mebatsion T. , Weiland F. , Conzelmann K. K. . ( 1999; ). Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. . J Virol 73:, 242–250.[PubMed]
    [Google Scholar]
  34. Morimoto K. , Hooper D. C. , Spitsin S. , Koprowski H. , Dietzschold B. . ( 1999; ). Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. . J Virol 73:, 510–518.[PubMed]
    [Google Scholar]
  35. Morimoto K. , Foley H. D. , McGettigan J. P. , Schnell M. J. , Dietzschold B. . ( 2000; ). Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. . J Neurovirol 6:, 373–381. [CrossRef] [PubMed]
    [Google Scholar]
  36. Müller T. , Johnson N. , Freuling C. M. , Fooks A. R. , Selhorst T. , Vos A. . ( 2007; ). Epidemiology of bat rabies in Germany. . Arch Virol 152:, 273–288. [CrossRef] [PubMed]
    [Google Scholar]
  37. Orbanz J. , Finke S. . ( 2010; ). Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters. . Arch Virol 155:, 1631–1641. [CrossRef] [PubMed]
    [Google Scholar]
  38. Préhaud C. , Wolff N. , Terrien E. , Lafage M. , Mégret F. , Babault N. , Cordier F. , Tan G. S. , Maitrepierre E. . & other authors ( 2010; ). Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. . Sci Signal 3:, ra5. [CrossRef] [PubMed]
    [Google Scholar]
  39. Pulmanausahakul R. , Li J. , Schnell M. J. , Dietzschold B. . ( 2008; ). The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. . J Virol 82:, 2330–2338. [CrossRef] [PubMed]
    [Google Scholar]
  40. Schnell M. J. , Mebatsion T. , Conzelmann K. K. . ( 1994; ). Infectious rabies viruses from cloned cDNA. . EMBO J 13:, 4195–4203.[PubMed]
    [Google Scholar]
  41. Serra-Cobo J. , Amengual B. , Abellán C. , Bourhy H. . ( 2002; ). European bat lyssavirus infection in Spanish bat populations. . Emerg Infect Dis 8:, 413–420. [CrossRef] [PubMed]
    [Google Scholar]
  42. Siler C. A. , McGettigan J. P. , Dietzschold B. , Herrine S. K. , Dubuisson J. , Pomerantz R. J. , Schnell M. J. . ( 2002; ). Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. . Virology 292:, 24–34. [CrossRef] [PubMed]
    [Google Scholar]
  43. Smith D. J. , Lapedes A. S. , de Jong J. C. , Bestebroer T. M. , Rimmelzwaan G. F. , Osterhaus A. D. , Fouchier R. A. . ( 2004; ). Mapping the antigenic and genetic evolution of influenza virus. . Science 305:, 371–376. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.048827-0
Loading
/content/journal/jgv/10.1099/vir.0.048827-0
Loading

Data & Media loading...

Supplementary material 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error